Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—The Phase III MECCA Trial

The MECCA trial demonstrated a significant improvement in progression-free survival and overall survival with first-line metronomic capecitabine plus aromatase inhibitor (AI) compared with AI alone in patients with hormone receptor-positive+/HER2-negative metastatic breast cancer.